TIGLUTIK KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TIGLUTIK KIT (TIGLUTIK KIT).
Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.
| Metabolism | Hepatic metabolism primarily via CYP1A2, with minor contributions from CYP3A4 and glucuronidation. |
| Excretion | Riluzole is primarily eliminated via hepatic metabolism, with <10% excreted unchanged in urine. Metabolites are eliminated renally (~85%) and fecally (~5%). |
| Half-life | Terminal elimination half-life is approximately 9-15 hours, with a mean of 12 hours. Steady-state is reached within 5-7 days. Clinically, this supports twice-daily dosing. |
| Protein binding | 97% bound primarily to plasma proteins, including albumin and lipoproteins. |
| Volume of Distribution | Approximately 3.4 L/kg, indicating extensive tissue distribution, particularly into the CNS. |
| Bioavailability | Oral bioavailability is approximately 60% (range 36-76%) due to extensive first-pass metabolism. High-fat meals reduce AUC by 20% and Cmax by 45%. |
| Onset of Action | The onset of clinical effect (neuroprotective) is not immediate; therapeutic benefit is observed after weeks to months of continuous dosing. No acute effect. |
| Duration of Action | Duration of action is approximately 12 hours due to twice-daily dosing. Consistent plasma levels are required for sustained neuroprotection. |
50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/mL oral suspension packet with 10 mL of water.
| Dosage form | SUSPENSION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl 30-89 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) due to lack of data. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B), but use with caution. |
| Pediatric use | Not approved for pediatric patients under 18 years of age. Safety and efficacy have not been established. |
| Geriatric use | No specific dose adjustment recommended based on age alone; consider renal function and overall frailty. Monitor for adverse effects, particularly falls and dysphagia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TIGLUTIK KIT (TIGLUTIK KIT).
| Breastfeeding | Excretion into human milk unknown; M/P ratio not established. Caution advised; consider discontinuing nursing or drug based on importance to mother. |
| Teratogenic Risk | FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefit justifies risk. Second/third trimesters: possible fetal growth restriction; avoid if possible. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to riluzole or any component of the formulation","Concomitant use with tizanidine","Severe hepatic impairment (Child-Pugh class C)"]
| Precautions | ["Hepatic injury (elevated transaminases, bilirubin)","Neutropenia","Interstitial lung disease","Dizziness and somnolence"] |
Loading safety data…
| Monitor maternal liver function (ALT, AST) monthly; fetal ultrasound for growth restriction and anomalies; respiratory status for aspiration risk. |
| Fertility Effects | In animal studies, no adverse effects on fertility at therapeutic doses; human data lacking. |